Dulaglutide and Tirzepatide Litigation British Columbia Class Action On February 11, 2026, Siskinds filed a proposed class action in the Supreme Court of British Columbia, alleging that dulaglutide drugs (Trulicity) and tirzepatide drugs (Mounjaro, Zepbound) manufactured and marketed by the Eli Lilly group of pharmaceutical companies were defective, and that the manufacturers failed to adequately warn users, and their health care providers, that semaglutide drugs increase the risk of serious complications, including gallbladder disorders, severe gastrointestinal injuries (including gastroparesis, or stomach paralysis), blood clots, aspiration during surgery, necrotizing pancreatitis, malnutrition, and vision loss (non-arteritic anterior ischemic optic neuropathy)
-3 and -6 polyunsaturated fatty acids, obesity and cancer
This is the part most of you came here for, so Ill keep it practical
Fu H, Sun Y, Shao Y
Inside: your vial(s) in protective packaging, your printed Janoshik COA where applicable, ten insulin syringes for vial orders, four sterile alcohol prep wipes, and a small printed handling-and-reconstitution card on the inside of the lid
"And take your allergy pills before you do those things, to make sure that you're going to have less of a reaction. For more information, visit OSF HealthCare
